• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Novartis' Sandoz, following Pfizer's lead, launches 2nd carcinogen-related drug...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 23, 2022 at 11:02: PM
via Right on the heels of Pfizer’s Accuretic recall, nitrosamine impurities have forced another major drugmaker to pull certain meds from U.S. shelves.

Novartis’ Sandoz is recalling 13 lots of oral orphenadrine citrate 100-mg extended-release tablets after testing flagged unacceptable levels of a potential carcinogen dubbed NMOA, or Nitroso-Orphenadrine.

article source
 




Top Bottom
Back
Quote